#1COPYRIGHT © ABCELLERA Q1 2022 BUSINESS UPDATE MAY 10, 2022 AbCellera#2Q1 2022 BUSINESS UPDATE COPYRIGHT © ABCELLERA 2 DISCLAIMER This presentation contains forward-looking statements, including statements made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. The forward-looking statements are based on management's beliefs and assumptions and on information currently available to management. All statements contained in this presentation other than statements of historical fact are forward-looking statements, including statements regarding our ability to develop, commercialize and achieve market acceptance of our current and planned products and services, our research and development efforts, and other matters regarding our business strategies, use of capital, results of operations and financial position, and plans and objectives for future operations. In some cases, you can identify forward-looking statements by the words "may," "will," "could,” “would,” “should," “expect," "“intend," "plan," "anticipate," "believe," "estimate," "predict," "project,” “potential," "continue," "ongoing" or the negative of these terms or other comparable terminology, although not all forward-looking statements contain these words. These statements involve risks, uncertainties and other factors that may cause actual results, levels of activity, performance, or achievements to be materially different from the information expressed or implied by these forward-looking statements. These risks, uncertainties and other factors are described under "Risk Factors," "Management's Discussion and Analysis of Financial Condition and Results of Operations" and elsewhere in the documents we file with the Securities and Exchange Commission from time to time. We caution you that forward-looking statements are based on a combination of facts and factors currently known by us and our projections of the future, about which we cannot be certain. As a result, the forward-looking statements may not prove to be accurate. The forward-looking statements this presentation represent our views as of the date hereof. We undertake no obligation to update any forward-looking statements for any reason, except as required by law.#3STRONG RESULTS & FOCUS ON KEY PRIORITIES Ab Cellera Q1 2022. BUSINESS UPDATE SUMMARY. 2 NEW programs under contract 6 NEW programs started 1 MOLECULE entered the clinic 158 cumulative programs under contract 84 cumulative programs started >$780M in cash, cash equivalents & marketable securities#4Q1 2022 BUSINESS UPDATE COPYRIGHT © ABCELLERA 4 THE BEST CAPABILITIES IN THE WORLD FROM TARGET TO IND TARGETS SPECIFICATIONS WORKFORCE IND Engine TECHNOLOGY SOFTWARE + DATA SCIENCE INFRASTRUCTURE 2x faster solve the unsolvable highest quality unprecedented scale COMPOSITION OF MATTER Patentable DNA sequence of the drug IND Investigational New Drug Application DRUG SUBSTANCE GMP material for clinical testing#5Q1 2022 BUSINESS UPDATE COPYRIGHT © ABCELLERA 5 PARTNERSHIPS DEAL STRUCTURES THAT CAPTURE DOWNSTREAM VALUE We expanded our existing partnership with Empirico to 7 targets, and the new agreement provides us with the option, on a program-by- program basis, to co-invest in preclinical and clinical development in exchange for a greater ownership stake in the program. In the event we continue to co-invest, we will maintain a 50% interest in each program. EMPIRICO A NEXT GENERATION THERAPEUTICS COMPANY 7 targets multi-year Qmultiple indications#6Q1 2022 BUSINESS UPDATE COPYRIGHT © ABCELLERA 6 TECHNOLOGY DEVELOPMENT: T CELL ENGAGER PLATFORM A DIVERSE PANEL OF CD3 ANTIBODIES TO CREATE NEW CANCER THERAPIES We used our technology to find hundreds of CD3-binding antibodies that can be combined to create precision cancer therapies. We then used our clinically-validated bispecifics platform, OrthoMab™ to pair the CD3-binding antibodies with a single EGFR- binding arm and confirm their function. CD3-binding antibodies Diverse Developable tumor-binding antibodies Validated#7o COPYRIGHT © ABCELLERA Q1 2022 FINANCIALS UPDATE#8FINANCIALS Q1 2022 BUSINESS UPDATE COPYRIGHT © ABCELLERA 8 Strong portfolio growth. Total # of Programs Under Contract Total # of Discovery Partners 36 158 Cumulative # of Program Starts 90 80 70 60 50 40 30 20 10 O 84 2014 2015 2016 2017 2018 2019 2020 2021 2022 Q1 WITHOUT downstream participation + WITH downstream participation 6 5 4 3 2 1 O Cumulative # of Molecules in the Clinic 6 2014 2015 2016 2017 2018 2019 2020 2021 2022 Q1 Note: Showing year-end figures except for most recent quarter. Historical results are not necessarily indicative of future results.#9FINANCIALS Q1 2022 BUSINESS UPDATE COPYRIGHT © ABCELLERA 9 6 molecules in the clinic, 2 authorized for emergency use. MOLECULE bamlanivimab (LY-CoV555) bebtelovimab (LY-CoV1404) NBL-012 NBL-015 NEW undisclosed IVX-01 STAGE Marketed, Emergency Use Authorization (EUA) Marketed, Emergency Use Authorization (EUA) Phase I IND approved IND approved Clinical field study PARTNER Lilly Lilly NovaRock BOTHERAPEUTICS NovaRock BIOTHERAPEUTICS undisclosed Invetx™ THERAPEUTIC AREA ● ● ● ● ● ● ● ● infectious disease - COVID-19 infectious disease - COVID-19 dermatology gastrointestinal disease immunology oncology undisclosed animal health PROGRAM TYPE AbCellera Discovery Partnership Trianni License AbCellera Discovery Partnership As of March 31, 2022#10FINANCIALS Q1 2022 BUSINESS UPDATE COPYRIGHT © ABCELLERA 10 $316.5M total revenue, driven by royalties for bamlanivimab and bebtelovimab. Revenue USD ROYALTIES MILESTONES LICENSING RESEARCH FEES $202.8M $171.5M $7.0M $4.0M Q1 2021 $20.3M $316.5M $307.0M $9.3M $0.2M Q1 2022#11FINANCIALS Q1 2022 BUSINESS UPDATE COPYRIGHT © ABCELLERA 11 Operating expenses reflect strengthening of the platform. Operating Expenses USD RESEARCH & DEVELOPMENT $12.4M Q1 2021 +$14.0M $26.4M Q1 2022 SALES & MARKETING $2.6M Q1 2021 -$0.2M $2.4M Q1 2022 GENERAL & ADMIN $6.5M Q1 2021 +$7.8M $14.3M Q1 2022#12FINANCIALS Q1 2022 BUSINESS UPDATE COPYRIGHT © ABCELLERA 12 Net earnings of $168.6M: equivalent to $0.59 (basic) and $0.54 (diluted) per share. Earnings USD NET EARNINGS $117.1M Q1 2021 $168.6M Q1 2022 EARNINGS PER SHARE: BASIC $0.43 2021 Q1 $0.59 2022 Q1 EARNINGS PER SHARE: DILUTED $0.37 2021 Q1 $0.54 2022 Q1#13FINANCIALS Q1 2022 BUSINESS UPDATE COPYRIGHT © ABCELLERA 13 Over $780 million in total cash, equivalents, and marketable securities. Cash Flows USD $748M $247M $476M $25M 31-Dec-21 $100M OPERATING ($26M) INVESTING ($3M) FINANCING $OM FX $812M $240M Marketable Securities $547M Cash & Equivalents $25M Restricted Cash 31-Mar-22#1414 COPYRIGHT © ABCELLERA 15 Q1 2022 BUSINESS UPDATE YOU THANK